This year, Russia will create a test system to assess the safety of biomedical cell products (BMCP), Deputy Prime Minister Tatyana Golikova said at a meeting of Russia’s Presidential Council for Science and Education.
“This year, eight cellular products have been selected that have passed the preclinical trials; they restore a patient’s capacity for work and reduce the risk of disability in joint diseases, bone fractures, relieve the consequences of stroke, spinal injuries, burns and trophic ulcers,” Golikova said.
Clinical studies planned to be conducted at the Lomonosov Moscow State University, the Russian Scientific Center of Surgery named after Academician Petrovsky, Koltzov Institute of Developmental Biology, and a number of other institutes. The same institutions will train health workers and ensure the adoption of new treatment methods in practical healthcare.
By the end of the year, it is planned to complete clinical trials of 11 original drugs. The therapies target cancer and cardiovascular system diseases, the Deputy Prime Minister said.
